Similar articles

• Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H).

  Hirst C, Raasch S, Llewelyn G, Robertson N. Hirst C, et al. J Neurol Neurosurg Psychiatry. 2006 Jun;77(6):800-2. doi: 10.1136/jnnp.2005.076869. J Neurol Neurosurg Psychiatry. 2006. PMID: 16705208 Free PMC article. No abstract available.
• Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy.

  Marsh EA, Hirst CL, Llewelyn JG, Cossburn MD, Reilly MM, Krishnan A, Doran M, Ryan AM, Coles AJ, Jones JL, Robertson NP. Marsh EA, et al. J Neurol. 2010 Jun;257(6):913-9. doi: 10.1007/s00415-009-5437-3. Epub 2010 Jan 6. J Neurol. 2010. PMID: 20049473 Clinical Trial.
• [Alemtuzumab in early multiple sclerosis].

  Killestein J, Polman CH. Killestein J, et al. Ned Tijdschr Geneeskd. 2009 Jan 10;153(1-2):46. Ned Tijdschr Geneeskd. 2009. PMID: 19198214 Dutch. No abstract available.
• Alemtuzumab.

  Ravandi F, O'Brien S. Ravandi F, et al. Expert Rev Anticancer Ther. 2005 Feb;5(1):39-51. doi: 10.1586/14737140.5.1.39. Expert Rev Anticancer Ther. 2005. PMID: 15757437 Review.
• [Clinical guideline review: Guillain-barre syndrome and chronic inflammatory demyelinating polyneuropathy].

  Mori K, Hattori N, Sobue G. Mori K, et al. Nihon Naika Gakkai Zasshi. 2002 Aug 10;91(8):2443-57. Nihon Naika Gakkai Zasshi. 2002. PMID: 12373856 Review. Japanese. No abstract available.